{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:27:36Z","timestamp":1767994056174,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Intas Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.hoc.2018.07.008","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T12:21:04Z","timestamp":1541074864000},"page":"1041-1055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting Angiogenesis"],"prefix":"10.1016","volume":"32","author":[{"given":"Neesha C.","family":"Dhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.hoc.2018.07.008_bib1","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/1541-7786.MCR-12-0353","article-title":"Revisiting the complexity of the ovarian cancer microenvironment--clinical implications for treatment strategies","volume":"10","author":"Musrap","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.008_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.leu.2404402","article-title":"The history of the angiogenic switch concept","volume":"21","author":"Ribatti","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2018.07.008_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PPO.0000000000000138","article-title":"The contribution of angiogenesis to the process of metastasis","volume":"21","author":"Bielenberg","year":"2015","journal-title":"Cancer J"},{"key":"10.1016\/j.hoc.2018.07.008_bib4","first-page":"3","article-title":"Therapeutic inhibition of angiogenesis","volume":"46","author":"Zhang","year":"2001","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.hoc.2018.07.008_bib5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/OPTH.S31016","article-title":"Emerging roles for antiangiogenesis factors in management of ocular disease","volume":"6","author":"Saeed","year":"2013","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.hoc.2018.07.008_bib6","first-page":"591","article-title":"Anti-angiogenic agents for the\u00a0treatment of solid tumors: potential pathways, therapy and current strategies - a review","volume":"8","author":"Al-Abd","year":"2017","journal-title":"J\u00a0Adv Res"},{"issue":"10043","key":"10.1016\/j.hoc.2018.07.008_bib7","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.008_bib8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1258\/0007142001903364","article-title":"Angiogenesis and its control in the female reproductive system","volume":"56","author":"Fraser","year":"2000","journal-title":"Br Med Bull"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.008_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2008.11.030","article-title":"Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study","volume":"112","author":"Rubatt","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2018.07.008_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1054\/bjoc.2000.1228","article-title":"Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma","volume":"83","author":"Shen","year":"2000","journal-title":"Br J Cancer"},{"issue":"58","key":"10.1016\/j.hoc.2018.07.008_bib11","doi-asserted-by":"crossref","first-page":"97851","DOI":"10.18632\/oncotarget.18415","article-title":"Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients","volume":"8","author":"Avril","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.hoc.2018.07.008_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1471-2407-10-139","article-title":"TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients","volume":"10","author":"Mahner","year":"2010","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.hoc.2018.07.008_bib13","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2007.12.1509","article-title":"Experience with bevacizumab in the management of epithelial ovarian cancer","volume":"25","author":"Burger","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"33","key":"10.1016\/j.hoc.2018.07.008_bib14","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"33","key":"10.1016\/j.hoc.2018.07.008_bib15","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2018.07.008_bib16","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.008_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2012.11.038","article-title":"Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study","volume":"128","author":"Monk","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2018.07.008_bib18","unstructured":"Ray-Coquard I, Cibula D, Mirza MR. AGO-OVAR12: a randomized placebo-controlled GCIC\/ENGOT-Intergroup phase III trial with chemotherapy\u00a0+\/- nintedanib for advanced ovarian cancer: overall survival results. Paper presented at: 2017 ESGO Congress. Vienna, Austria, November 4\u20137, 2017."},{"issue":"30","key":"10.1016\/j.hoc.2018.07.008_bib19","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.008_bib20","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/annonc\/mdx796","volume":"29","author":"Friedlander","year":"2018","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2018.07.008_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/ijgc-00009577-200505001-00007","article-title":"Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer","volume":"15","author":"Pfisterer","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"20","key":"10.1016\/j.hoc.2018.07.008_bib22","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2018.07.008_bib23","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.hoc.2018.07.008_bib24","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2018.07.008_bib25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10023","key":"10.1016\/j.hoc.2018.07.008_bib26","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.hoc.2018.07.008_bib27","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/cncr.30657","article-title":"Quality of life with cediranib in relapsed ovarian cancer: the ICON6 phase 3 randomized clinical trial","volume":"123","author":"Stark","year":"2017","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.hoc.2018.07.008_bib28","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 9","key":"10.1016\/j.hoc.2018.07.008_bib29","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0959-8049(01)00330-6","article-title":"Phase III data on Caelyx in ovarian cancer","volume":"37","author":"Muggia","year":"2001","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2018.07.008_bib30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/annonc\/mdr149","article-title":"Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)","volume":"23","author":"Lortholary","year":"2012","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2018.07.008_bib31","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1200\/JCO.2007.15.1258","article-title":"Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"26","author":"Sehouli","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2018.07.008_bib32","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2018.07.008_bib33","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdx228","article-title":"Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial","volume":"28","author":"Bamias","year":"2017","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.hoc.2018.07.008_bib34","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.008_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","article-title":"Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2","volume":"143","author":"Monk","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.hoc.2018.07.008_bib36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2016.09.004","article-title":"ENGOT-ov-6\/TRINOVA-2: randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer","volume":"70","author":"Marth","year":"2017","journal-title":"Eur J Cancer"},{"issue":"26","key":"10.1016\/j.hoc.2018.07.008_bib37","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.008_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2018.07.008_bib39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.008_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1078155217690921","article-title":"Association of hypertension and treatment outcomes in advanced stage non-small cell lung cancer patients treated with bevacizumab or non-bevacizumab containing regimens","volume":"24","author":"Yan","year":"2018","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.008_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1634\/theoncologist.2012-0339","article-title":"Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.hoc.2018.07.008_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.gore.2016.06.002","article-title":"Bevacizumab induced hypertension in gynecologic cancer: does it resolve after completion of therapy?","volume":"17","author":"Corr","year":"2016","journal-title":"Gynecol Oncol Rep"},{"issue":"2","key":"10.1016\/j.hoc.2018.07.008_bib43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2014.08.033","article-title":"The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer","volume":"135","author":"Secord","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2018.07.008_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx066","article-title":"Tumor microvessel density as a potential predictive marker for Bevacizumab benefit: GOG-0218 biomarker analyses","volume":"109","author":"Bais","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2018.07.008_bib45","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/jco.2015.33.15_suppl.5505","article-title":"Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin\u2013paclitaxel (CP) \u00b1 bevacizumab (BEV) for epithelial ovarian cancer (EOC)","volume":"33","author":"Birrer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2018.07.008_bib46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/bjc.2016.194","article-title":"Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab","volume":"115","author":"Zhou","year":"2016","journal-title":"Br J Cancer"},{"issue":"Suppl 15","key":"10.1016\/j.hoc.2018.07.008_bib47","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1200\/jco.2014.32.15_suppl.5502","article-title":"Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab","volume":"32","author":"Gourley","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.hoc.2018.07.008_bib48","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","article-title":"BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study","volume":"140","author":"Harter","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2018.07.008_bib49","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/1078-0432.CCR-17-1327","article-title":"Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology\/Gynecologic Oncology Group Study","volume":"24","author":"Norquist","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2018.07.008_bib50","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.008_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2013.11.008","article-title":"Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper","volume":"132","author":"Herzog","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.008_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2018.07.008_bib53","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IGC.0000000000000836","article-title":"Efficacy and safety of Bevacizumab-containing therapy in newly diagnosed ovarian cancer: ROSiA Single-Arm Phase 3B Study","volume":"27","author":"Oza","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"16","key":"10.1016\/j.hoc.2018.07.008_bib54","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1158\/1078-0432.CCR-07-0409","article-title":"Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses","volume":"13","author":"Fricke","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2018.07.008_bib55","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858818307585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858818307585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:11:55Z","timestamp":1760184715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858818307585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0889858818307585"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2018.07.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Angiogenesis","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2018.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}